Corcept Therapeutics stock
Price history
−7.85% over the period1 year: from $75.12 (November 17, 2025) to $69.23 (November 16, 2026), −7.85%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 16, 2026 | $69.23 |
| October 30, 2026 | $81.12 |
| September 30, 2026 | $115.23 |
| August 31, 2026 | $113.35 |
| July 31, 2026 | $114.49 |
| June 30, 2026 | $86.95 |
| May 29, 2026 | $69.49 |
| April 30, 2026 | $46.52 |
| March 31, 2026 | $40.31 |
| February 27, 2026 | $35.70 |
| January 30, 2026 | $39.87 |
| December 31, 2025 | $34.80 |
| November 28, 2025 | $79.40 |
| November 17, 2025 | $75.12 |
At a glance
The company
Biopharmaceutical company developing medications for severe endocrinologic, oncologic, metabolic and neurologic disorders
Latest results
Quarter to September 30, 2026 · EPS $1.01 (estimate $0.79)
TickerLandia's take on Corcept Therapeutics
- Pricier than usual relative to earnings: P/E on the latest fiscal year 84 vs a median of 27 over its last 10 fiscal years.
- Pricier than similar companies: trailing 12-month P/E 190 vs 61 (+213%) in a group of 6.
- Strong point: Growth (79/100 in its group). Weak point: Market momentum (36/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−45.22% from the 52-week high
Analysts · 5 analysts
Average target$141.00+103.68% vs. price
Buy 4 · Hold 0 · Sell 1 · Buy
TickerLandia Fingerprint: Corcept Therapeutics
Compared with similar companies: very high risk.
Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 883 North American stocks.
Priceaverage58
How much it costs relative to what it produces.
Metric Value Position in group Price/book 9.57 73 Price/sales 8.28 43 Forward P/E 14.6 21 P/E (trailing 12 months) 54.8 71 EV/EBITDA 67.4 80 Profitabilityhigh63
How much it earns on revenue and capital.
Metric Value Position in group Net margin 16.8% 55 Gross margin 98.5% 89 ROE 22.1% 75 Operating margin 11.5% 37 ROA 7.5% 59 Earnings stabilityhigh77
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 10.5% 70 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 84 Growthhigh79
How fast revenue and earnings are growing.
Metric Value Position in group Revenue growth (year over year) +64.00% 84 Average revenue growth (3 years) +23.74% 55 Earnings growth (year over year) +531.30% 97 Financial strengthhigh72
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Net debt/EBITDAcounts in reverse: lower means more financial strength · more cash than debt −2.49 88 Debt/equitycounts in reverse: lower means more financial strength 0.01 86 Current ratio 3.01 42 Dividendno dividend
How much it returns to shareholders, and for how long.
Market momentumweak36
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) −31.93% 4 Relative strength (6 months) +25.80% 83 Distance from 200-day average −4.65% 29 1-year return −3.71% 26 Riskvery high90
How much the price swings.
Metric Value Position in group Maximum drawdown (12 months) 63.5% 97 Volatility (60 days) 62.6% 87 Beta (1 year) 1.94 85
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Corcept Therapeutics is pricier than in the past and pricier than similar companies
On the latest fiscal year's earnings (2025), Corcept Therapeutics's P/E today is 84.4, above the median of its last 10 fiscal years (27.1; between 15.7 and 103.7 from 2016 to 2025). Corcept Therapeutics's P/E (trailing 12 months): 190.2, +213% against the median of a group of 6 similar companies (60.8).
Compared with 6 similar companies
| Metric | Corcept Therapeutics | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 190.2 | High | |
| Forward P/E | 16.5 | Middle | |
| Operating margin | 0.8% | Middle | |
| ROE | 8.2% | Middle | |
| Debt/equity | 0.01 | Low |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Corcept Therapeutics. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
$256.15M
Latest quarter · Q2 2026
Net income
$42.99M
Latest quarter · Q2 2026
Quarterly net margin
16.8%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- $9.36B
- P/E
- 190.2
- EPS
- $1.33
- Volume
- 617.25K
- Daily trading
- €97.71M
How Corcept Therapeutics is changing
All resultsRevenue grew 16.6% a year on average over the last 5 years
Operating margin fell from 28.0% to 5.9%
Profits turn into cash: free cash flow equal to 134% of net income
Returns
Corcept Therapeutics returns
$1,000 invested in Corcept Therapeutics 5 years ago, on November 16, 2021, would be worth $2,971 today: +197.10% in total, +24.34% per year. This is the price return only: dividends are excluded.
| Period | Corcept Therapeutics | S&P 500 | $1,000 becomes |
|---|---|---|---|
| 1 month | −37.16% | −3.12% | $628 |
| 6 months | +22.80% | +2.07% | $1,228 |
| Year to date | +98.92% | +10.46% | $1,989 |
| 1 year | −7.85% | +13.33% | $922 |
| 3 years | +175.69% | +67.73% | $2,757 |
| 5 years | +197.10% | +60.86% | $2,971 |
| 10 years | +631.77% | +247.35% | $7,318 |
Over the last 6 months it has done better than 58% of the stocks in the Healthcare sector.
Price only, without dividends. Calculate your investment
The chart in detail
Corcept Therapeutics: technical analysis
Corcept Therapeutics shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 44.0% below its all-time closing high ($123.57, August 25, 2026).
- Trend
- No clear trend
- RSI (14 sessions)
- 23
- Below 30: a strong fall in a short time
- vs 200-session average
- −9.68%
Active signals
Close below the low of the previous 55 sessions.
RSI below 30: the stock has fallen a lot in a short time.
since October 23, 2026
Support and resistance
Price areas where Corcept Therapeutics has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance$108.33+56.49%2 touches, last on September 18, 2026
- Resistance$89.50+29.29%2 touches, last on July 28, 2026
- Resistance$77.72+12.28%2 touches, last on June 22, 2026
- Last price$69.23
- Support$32.87−52.52%3 touches, last on March 13, 2026
Volatility and risk
Over the last year it has moved more than the S&P 500.
- Beta (1 year) vs S&P 500
- 1.95
- Volatility (60 sessions, annualised)
- 63.2%
- Largest fall in the last year
- −63.46%
In session, November 16, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Corcept Therapeutics: seasonality
Average monthly price change over 23 years
Over the last 23 years, the strongest month for Corcept Therapeutics has been March: +14.03% on average, positive in 17 years out of 22. The weakest has been October: −1.98% on average, positive in 11 years out of 23. November, the current month, has been positive in 11 years out of 22 (+1.93% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +2.09% | −0.26% | 11 of 22 |
| February | +0.83% | −1.75% | 9 of 22 |
| March | +14.03% | +7.51% | 17 of 22 |
| April | +0.62% | +1.39% | 12 of 22 |
| May | +2.51% | +2.82% | 12 of 23 |
| June | +5.29% | −1.80% | 11 of 23 |
| July | +0.86% | −5.10% | 11 of 23 |
| August | −0.68% | −1.00% | 9 of 23 |
| September | +6.12% | −0.70% | 11 of 23 |
| October | −1.98% | −1.86% | 11 of 23 |
| November | +1.93% | +3.88% | 11 of 22 |
| December | +2.97% | −0.84% | 9 of 22 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Corcept Therapeutics and its competitors
With 730 employees, Corcept Therapeutics develops medicines that modulate cortisol activity for conditions linked to excess cortisol. Its marketed product, Korlym, is prescribed in the United States to control blood sugar in adults with Cushing's syndrome who have type 2 diabetes or impaired glucose tolerance and who either did not respond to surgery or cannot undergo it. The pipeline includes relacorilant for hypercortisolism, miricorilant, which is in a Phase 1b study for metabolic dysfunction-associated steatohepatitis, and several cortisol modulators, among them dazucorilant, for Lou Gehrig's disease.
- Headquarters
- Redwood City, United States
- Employees
- 730
- Founded
- 1998
- Chief executive
- Joseph Belanoff
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| Corcept TherapeuticsCORT | $9.36B | 0.8% | 190.2 | +22.80% |
| Twist BioscienceTWST | $7.4B | -28.8% | — | +113.09% |
| Madrigal PharmaceuticalsMDGL | $9.93B | -10.7% | — | −18.72% |
| ImmunityBioIBRX | $6.4B | -150.2% | — | −24.28% |
| BioMarin PharmaceuticalBMRN | $11.09B | 16.3% | 146.8 | +12.23% |
| Summit TherapeuticsSMMT | $11.32B | 0.0% | — | −28.81% |
Same industry or related industries, similar size. Compare Corcept Therapeutics with its competitors · Full profile
